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Abstract 
Background: Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic 
encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue 
of 6 months or longer, particularly post exertion. No definitive biomarkers are available.
Methods: A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, 
in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin refer-
ence population were also performed. For the total study cohort the age range was 18–65 years with a female: male 
participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples 
were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, 
activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between 
the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference 
intervals.
Results: Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study 
controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. 
All routine and special pathology markers were within the normal laboratory reference intervals for the total study 
cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences 
were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma.
Conclusion: Elevated activin B levels together with normal activin A levels identified patients with the diagnostic 
symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and cap-
ture the diverse array of symptoms experienced by CFS/ME patients.
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Background
Chronic fatigue syndrome/myalgic encephalomyeli-
tis (CFS/ME) currently presents a diagnostic dilemma 
because of the multi-system nature of the symptoms and 
the lack of a definitive serum-based diagnostic. Diagnosis 
is currently based on clinical case definition criteria, of 
which the CDC-1994/Fukuda case definition is the most 
frequently applied [1], as evidenced from the twenty 
case definitions identified for systematic review (SR) by 
Brurberg et al. [2]. The same study also found few valida-
tion studies performed using the various diagnostic crite-
ria, confirming the nebulous aspects of diagnosis by case 
definition.
Efforts to improve the rigour of CFS/ME case defi-
nitions have included an update of the 2003 Canadian 
Criteria to the International Consensus Criteria in 2011 




*Correspondence:  brett.lidbury@anu.edu.au 
7 Present Address: The National Centre for Epidemiology and Public 
Health, The Research School of Population Health, ANU, Canberra, ACT 
2601, Australia
Full list of author information is available at the end of the article
Page 2 of 10Lidbury et al. J Transl Med  (2017) 15:60 
cognitive and physical deficiency, with less importance 
on psychiatric co-morbidity and depression when com-
pared to the Fukuda criteria. A more recent attempt to 
design clearer and simpler diagnostic criteria focused 
on post-exertional fatigue, and proposing the new name 
Systemic Exertion Intolerance Disease (SEID) [5], instead 
of ME and/or CFS. However, the diagnosis of the disease 
remains a challenge as the diagnostic criteria requires 
that patients experience the symptoms for at least 
6 months before a definitive diagnosis can be made, leav-
ing patients to struggle with the illness for a considerable 
time before being diagnosed.
Given that many patients often describe an influenza-
like illness preceding the development of CFS/ME, the 
possibility that cytokines may provide diagnostic markers 
of CFS/ME has been assessed, but with little consensus as 
to their diagnostic utility, possibly influenced by disease-
stage and other inter-patient variability. Evidence that 
the immune system is involved in CFS/ME is supported 
by low natural killer cell cytotoxicity [6], but to date an 
immune biomarker for CFS/ME has not been identified.
Given the accumulating data that activin A and B are 
involved in the control of inflammation and muscle mass 
[7], we undertook a cross-sectional study on the potential 
of activin A, activin B, and its binding protein (follistatin), 
as serum markers of CFS/ME, via a Melbourne clinic that 
works exclusively with CFS/ME patients. The activins are 
members of the Transforming Growth Factor β (TGFβ) 
family of proteins, and are dimers of subunits encoded 
by the INHBA (βA) and INHBB (βB) genes. The subunits 
dimerise to form activin A (βAβA) and activin B (βBβB) 
[7]. Our previous data show that in patients admitted to 
intensive care units (ICU) with acute respiratory distress, 
survival of up to 12-months post ICU can be predicted 
by the measurement of activin A and B levels during the 
first 5 days in ICU [8]. This may be a causal relationship, 
since increased activin A and activin B levels can induce a 
loss of muscle mass [9]. Interestingly, activin B is involved 
in inflammatory-induced anaemia via regulation of hep-
cidin expression [10], a function distinct from activin A.
In addition to immune dysregulation, the loss of muscle 
mass suggests that the activins are potentially involved in 
the pathogenesis of CFS/ME, given the prominence of 
muscle weakness and pain as diagnostic criteria across 
the various case definitions. Due to these associations, 
in addition to symptoms spanning cognitive and gastro-
intestinal functions, it was hypothesised that significant 
fluctuations of serum activin/follistatin levels and ratios 
were likely for CFS/ME patients formally diagnosed 
under the 2003 Canadian Criteria [3]. Here we report the 
outcomes of a study of serum activin A, B and follista-
tin levels in blood samples from 45 patients diagnosed 
with CFS/ME under the 2003 Canadian Criteria, whose 




Participants in this study included 45 patients (40 females 
and 5 males: age 19–66  years) diagnosed with chronic 
fatigue syndrome at the CFS Discovery Clinic, a primary 
care community clinic that works exclusively with CFS/
ME patients, located in Donvale (Victoria, Australia). 
Patients were diagnosed with CFS/ME if they fulfilled 
the Canadian Diagnostic Criteria, [3] as conducted by 
a medical practitioner and registered nurse both with 
15–20  years’ experience with CFS/ME patients. For 
the CFS/ME cohort, length of illness ranged from 2 to 
40  years. During the early phase of the study, the 2011 
International Criteria for CFS/ME diagnosis were pub-
lished, [4] but since the study had commenced partici-
pant recruitment and assessment under the 2003 criteria, 
the application of the 2003 criteria persisted for the dura-
tion of this study.
The study also recruited 17 healthy control participants, 
comprising 13 females and 4 males (age 24–60  years). 
Control participants were recruited via neighbouring 
clinics within the Doncaster district of East Melbourne, 
through CFS support groups and by word-of-mouth.
Research participants for this study were recruited over 
2011–2012 from patients attending CFS Discovery for 
the first time, often after long periods of interaction with 
the medical profession, but no conclusive diagnosis or 
successful treatment. While there are theories, the cause 
and/or exposure that results in CFS/ME symptoms are 
not known. A cross-sectional (observation) study design 
was applied, with CFS/ME cases and healthy controls 
attending only once for research involvement over the 
2011–2012 study period. Follow-up was provided as rou-
tine clinic attendance after the research interaction.
Study details
The assessment of patients at CFS Discovery was previ-
ously reported by Reynolds et al. [11] which included the 
protocol for orthostatic intolerance testing and results for 
autonomic markers of cardiac and circulatory function in 
CFS/ME patients, with key pathology and cytokine mark-
ers for this cohort summarised in Table  1. In addition 
to the formal CFS/ME diagnostic criteria, assessed by 
survey and physical examination, research participants 
were also screened for potentially confounding comor-
bidities. The study contained tests and clinical assess-
ments to exclude hypothyroidism, Lupus, Fibromyalgia 
(FM) and Multiple Chemical Sensitivity via the physical 
and mental status examinations. Also, conducted on each 
CFS/ME and control participant were routine blood and 
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urine tests, as described below and Table 1. Assessments 
of sleep patterns were ascertained via the Epworth Scale, 
and the DASS-36 scale applied to assess anxiety, depres-
sion and generalised stress. Recommended guidelines 
for CFS research also were consulted for this investiga-
tion [12], allowing consistent comparisons to other stud-
ies. The “Minimal Requirements” under these guidelines 
were generally captured by the application of the Cana-
dian Criteria to CFS/ME status.
A patient was classified as having CFS/ME if she or 
he met the above criteria and all other possibilities were 
excluded as listed above. If a patient’s fatigue was not 
severe enough, or if the symptom criteria for CFS/ME 
were not met, he or she was classified as having idio-
pathic chronic fatigue. Seventeen healthy controls were 
also recruited and assessed exactly as described for 
CFS/ME participants, including orthostatic intolerance 
testing to screen for autonomic comorbidities. Healthy 
participants could not be a relative of a previous or cur-
rent CFS/ME patient, or live at the same residential 
address.
All research participants were non-identifiable to the 
researchers, with individual identifiers removed from 
the data provided, except for a unique identification (ID) 
code. Because only ID codes were provided, no clinical 
details were attached to samples for activin/follistatin, 
cytokines and pathology testing, removing potential bias 
from test result reporting.
As a first attempt at a cross-sectional study on this 
CFS/ME cohort, a minimum of 30 participants for each 
group was planned for statistical robustness, and was 
achieved for the CFS/ME group. Only 17 healthy con-
trol participants were recruited within the designated 
study period, in spite of proactive study advertising and 
connection with other GP clinics in the district. In addi-
tion to the 17 recruited study controls, comparisons of 
serum activin/follistatin levels with a previously recruited 
healthy reference population (n = 141) [8] were also con-
ducted for validation.
Patient involvement
No patients were involved in the conception or design of 
this study, nor were patients asked for input at any stage 
of the project. A summary of project results is available 
to research patients, as stated in the participant informa-
tion pack, on request.
Activin and follistatin analyses
Non-fasting blood samples were collected from patients 
after the 20-min standing test and the concentrations of 
activin A, activin B and follistatin were measured in the 
serum isolated from these samples. Concentrations of 
activin A were determined using a two-site ELISA (using 
antibodies supplied by Oxford Brookes University) as 
previously published [13]. This assay measures both free 
and follistatin-bound activin A dimers and has no sig-
nificant cross-reaction with other activin isoforms, such 
as activin B. Activin B was measured by two-site ELISA, 
as previously described (using antibodies supplied by 
Oxford Brookes University) [14]. Follistatin concentra-
tions were determined using an extensively validated 
radioimmunoassay [15]. Mean activin/follistatin con-
centrations were compared between the CFS/ME and 
control cohorts recruited for this study. Further analyses 
were performed comparing the recruited CFS/ME cohort 
Table 1 CFS/ME and  healthy study control participant 
profile comparisons via  representative pathology blood 
markers and cytokines
Analyses comprised healthy controls (n = 17) and the CFS/ME cohort (n = 45), 
except for cytokine and GTT studies that compared n = 8–10 controls with 
n = 38–44 CFS/ME. Statistical significance was calculated by unpaired Mann–
Whitney test
GTT glucose tolerance test
Assay or measurement Study cohort Mean ± SEM p value
Age (years) Control 36.83 ± 2.03 0.78
CFS/ME 37.69 ± 1.78
Haemoglobin (g/L) Control 140.89 ± 2.48 0.64
CFS/ME 139.13 ± 2.12
Thyroid stimulating hormone 
(mIU/L)
Control 1.38 ± 0.16 0.72
CFS/ME 1.45 ± 0.10
Vitamin D (nmol/L) Control 73.61 ± 7.73 0.71
CFS/ME 76.64 ± 3.99
Anion gap (mmol/L) Control 11.49 ± 0.55 0.14
CFS/ME 10.62 ± 0.30
GTT–blood glucose 30 min 
post load (mmol/L)
Control 7.15 ± 0.52 0.45
CFS/ME 7.66 ± 0.27
GTT–blood insulin 30 min  
post load (mU/L)
Control 50.88 ± 9.80 0.07
CFS/ME 81.33 ± 6.76
Interleukin-2 (pg/mL) Control 0.22 ± 0.12 0.09
CFS/ME 0.54 ± 0.11
Interleukin-4 (pg/mL) Control 0.26 ± 0.14 0.15
CFS/ME 0.55 ± 0.11
Interleukin-6 (pg/mL) Control 0.86 ± 0.25 0.20
CFS/ME 1.37 ± 0.20
Interleukin-10 (pg/mL) Control 1.06 ± 0.16 0.43
CFS/ME 1.18 ± 0.09
Interleukin-17A (pg/mL) Control Not detected N/A
CFS/ME Not detected
Interferon-γ (pg/mL) Control 0.57 ± 0.20 0.31
CFS/ME 0.37 ± 0.11
Tumour necrosis factor (pg/
mL)
Control Not detected N/A
CFS/ME Not detected
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to data previously collected to calculate reference inter-
vals for each marker.
Pathology and cytokine analyses
In addition to the blood samples collected for activin/fol-
listatin testing, blood was also drawn for pathology test-
ing at Australian Clinical Laboratories (Clayton, Victoria). 
Tests performed on each CFS/ME and control participant 
were routine full (complete) blood count examinations, 
multiple biochemical analyses that included liver and 
kidney function tests (with 24-h urine analysis), vitamin 
D (25-OH), parathyroid hormone (PTH), dehydroepi-
androsterone sulfate (DHEAS), immunoglobulin (Ig) E, 
antinuclear antibodies (ANA) and thyroid stimulating 
hormone (TSH). A fasting glucose tolerance test (GTT) 
was performed on a separate day post clinic consultation 
with blood glucose and insulin measured before glucose 
load (75 g in 200 mL), then at 30 and 60 min post glucose 
load.
Chronic fatigue syndrome/myalgic encephalomyelitis 
and control sera were also investigated for interleukin-2 
(IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), inter-
leukin-10 (IL-10), interleukin-17A (IL-17A), tumour 
necrosis factor (TNF) and interferon-gamma (IFN-γ). 
The seven cytokines were simultaneously quantitated 
via multiplex cytometric bead array (human CBA kit, 
catalogue number 560484, BD Biosciences, North Ryde, 
NSW), with data acquisition and analysis conducted on a 
BD FACS Calibur (JCSMR FACS Unit, ANU, Canberra).
Statistical analyses
Comparisons of means or medians between CFS/ME 
and control groups were performed by independent t 
test or Mann–Whitney tests respectively, depending on 
data distribution within the sample and whether the data 
were continuous or ordinal, with statistical significance 
accepted at p  <  0.05. Whether data followed a normal 
distribution, or not, was determined by a one-sample 
Kolmogorov–Smirnov (K–S) Test (SPSS version 22). Data 
are presented as mean ± SEM.
Chi square (χ2) was calculated to determine the statis-
tical significance (p < 0.05) of the frequency of elevated 
anti-nuclear antibodies (ANA ≥  160) between CFS/ME 
and study control cohorts. Receiver operating curves 
(ROC) were constructed using SPSS (version 22.0) soft-
ware, and calculated the area under curve (AUC ± SEM) 
to distinguish CFS/ME from healthy control cases, using 
a non-parametric model.
Pathology and activin/follistatin results had no miss-
ing data. Missing data was common for the seven serum 
cytokines measured, and recorded as not detected (ND). 
Cases with missing data were excluded from the analy-
ses. Mean ± SEM were not reported for TNF and IL-17A 
since protein was detected in only 2–3 samples across the 
CFS/ME and control cohorts.
Study approval
All research participants included in this study provided 
full, signed consent as dictated by the guidelines of the 
ANU Human Research Ethics Committee (ANU-HREC). 
This study and associated protocols were conducted 




Routine medical and pathology analyses of 45 patients 
(40 females and 5 males, age 19–66 years, length of ill-
ness 2 to 40  years) diagnosed with CFS/ME under the 
Canadian Diagnostic Criteria, and 17 healthy controls 
(13 females, 4 males; age 24–60 years), were conducted. 
Key assay markers measured in patients diagnosed with 
CFS/ME were all within laboratory reference intervals 
(Table  1). Other routine tests included liver function 
tests, urea, electrolytes and creatinine, as well as eryth-
rocyte and leukocyte markers/indices, with all results 
falling within the laboratory reference interval for CFS/
ME and control cohorts. In addition, dihydroepiandros-
teronesulphate (DHEAS), parathyroid hormone (PTH) 
and IgE were measured, but also showed no significant 
differences (p = 0.39 to 0.83, Mann–Whitney). The fre-
quency of positive antinuclear antibody (ANA) detection 
(≥160), a marker for autoimmune disorders, was not sta-
tistically significant (χ2 = 2.9, df = 1, p = 0.41) between 
CFS/ME and control groups. Also, no significant differ-
ences between CFS/ME and healthy participants were 
detected for blood glucose and insulin at 30-min after 
glucose loading, during an oral glucose tolerance test 
(GTT).
Table  2 summarises the physical characteristics and 
symptom profile against the Canadian Criteria for the 
CFS/ME cohort investigated. Healthy controls were sig-
nificantly taller (p = 0.002), while diastolic blood pressure 
and pulse rate (p  <  0.05) were significantly elevated for 
the CFS/ME cohort. All CFS/ME participants reported 
the key symptoms of fatigue for greater than 6  months 
and post-exertional fatigue (“payback”), as well as limited 
activity, unrefreshing sleep, impaired thinking/speech 
and orthostatic intolerance (Table  2). The prevalence 
of other symptoms under the Canadian Criteria varied 
from approximately 50% of the CFS/ME cohort to less 
than 10% (Table 2). Participants from the healthy control 
cohort occasionally reported headache, gut upset or dif-
ficulties waking from sleep, but these cases were sporadic 
and when reported involved only 1–2 participants from 
the total cohort.
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Activin and follistatin responses in CFS/ME and healthy 
control participants
Measurement of activin A, activin B and follistatin lev-
els in serum samples from the patient and control groups 
were conducted using validated assays to determine the 
clinical utility of these proteins as biomarkers. Levels of 
activin B, but not activin A and follistatin, were found 
to be significantly elevated (p = 0.002) in patient serum 
samples compared to control subjects (Fig. 1). The activin 
B response was unique as in addition to activin A, the 
levels of the other cytokines measured, namely IL-2, IL-4, 
IL-6, IL-10, IL-17A, TNFα and IFN-γ, were not statisti-
cally significant between groups (Table  1: IL-17A was 
detected in 2/45 CFS/ME samples and no controls, while 
serum TNFα was detected in 3/45 CFS/ME samples and 
no controls). Despite the significant elevation of activin 
B, the ratio of activin B to follistatin (ActB:FST), was 
not found to reach significance with respect to controls 
(p = 0.096) (Fig. 1d).
Receiver operating curves (ROC) were calculated from 
the CFS/ME versus healthy study controls data for activin 
A, activin B, follistatin and IL-10. IL-10 was chosen since 
previous observations suggested a significant role for this 
cytokine in CFS/ME. The calculated AUC for activin B 
was 72.4% (0.724 ± 0.076), which was significantly inde-
pendent (p =  0.010) from the 50% (0.5) AUC threshold 
(Fig. 2a). For activin A, follistatin and IL-10 (Fig. 2b–d), 
AUC results ranged from 0.467 to 0.567 and were not sig-
nificant (p = 0.43–0.70).
CFS/ME activin analyses in relation to a normal reference 
population
Prior to this study, 141 healthy volunteers were recruited 
by de Kretser et al. [8] to determine the serum reference 
intervals for activin A, activin B and follistatin, including 
the ratios of the activins A and B to follistatin (ActA:FST 
and ActB:FST) in a normal population (referred to herein 
as reference data to distinguish it from the study con-
trol group). This reference data was established using 
the same validated assays used to measure the samples 
obtained for this study. When comparing the data to 
this reference range, CFS/ME patients had a significantly 
higher activin B (p < 0.0001), but not activin A levels 
(Fig. 3a, b), suggesting an important relationship between 
Table 2 Summary of physical features and diagnostic symptom profile for the CFS/ME cohort investigated for cytokine 
and activin/follistatin variation
Epworth sleep scale: 0–10 (normal daytime sleepiness): 11–15 (excessive daytime sleepiness): 16–24 (severe daytime sleepiness)
Height was significantly greater for the healthy control cohort (p = 0.002, Mann–Whitney U). Diastolic blood pressure and pulse rate were significantly elevated for 
CFS/ME (p < 0.05, Mann–Whitney U). CFS/ME (n = 40 to 43); Healthy Controls (n = 7 to 17)
BMI body mass index, bpm beats per minute
Measurement Median (range)
CFS/ME cohort Healthy control cohort
Height (cm) 165.0 (122–188) 171.5 (153–187)
Weight (kg) 60.0 (52–124) 66.0 (51–98)
BMI 22.2 (18.9–47.2) 21.9 (19.6–32.1)
Blood pressure
 Systolic (mmHg) 120.0 (102–168) 121.5 (107–140)
 Diastolic (mmHg) 80.0 (65–104) 74.0 (55–90)
 Pulse rate (bpm) 72.0 (51–102) 60.0 (43–89)
Epworth sleep scale 6.0 (0–20) 4.0 (0–15)
Canadian criteria symptoms (percentage) CFS/ME cohort
Reported by 100% of study participants Fatigue ≥6 months Post-exertional fatigue
Activity limited Stress with activity
Unrefreshing sleep Reduced concentration
Impaired thinking + speech Orthostatic intolerance
Vertigo Food intolerance
Reported by ~50% of study participants Gut axis (constipation, indigestion, diarrhoea) Sleep (difficulty to wake, sleeping during day)
New allergies Sighing breaths
Arrhythmia Confusion
Smell sensitivity
Reported by ≤10% of study participants Migraine headache Sensitivity to touch
High heart rate upright Pain frequency
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activin B and CFS/ME. The control group data were 
within the reference range.
Comparisons to the reference data also showed that 
follistatin levels were significantly lower in the CFS/ME 
group (p  <  0.0001) (Fig.  3c), and therefore, both activin 
A:follistatin (ActA:FST, p < 0.015) and activin B:follistatin 
(ActB:FST, p  <  0.0001) ratios were significantly higher 
in CFS/ME patients (Fig.  3d, e), with a greater differ-
ence seen for the activin B/follistatin ratio. Concordantly, 
activin B levels relative to activin A levels (ActB: ActA 
ratio) were significantly elevated in CFS/ME patients 
(p  <  0.0001) compared to the reference data (Fig.  3f ). 
These data show that activin B levels, as well as activin A 
or B to follistatin ratios, were elevated above the normal 
range in patients with CFS/ME.
Discussion
Chronic fatigue syndrome/myalgic encephalomyelitis is 
a disorder that causes unexplained, persistent and some-
times disabling fatigue, with no definitive diagnostic tests 
available. Patients with this illness experience frustra-
tion due to health care provider difficulties in reaching 
a diagnosis of CFS/ME, compounded by the range and 
variation of the available diagnostic criteria [2]. It is esti-
mated that around 0.4% of people world-wide suffer from 
CFS/ME [16] and the Centres for Disease Control and 
Prevention in the USA has declared it a priority disease, 
along with TB and AIDS. With the majority of affected 
patients not receiving the correct diagnosis, and there-
fore never receiving the proper medical care for their 
illness [5], there is a pressing need for a diagnostic bio-
marker to assist these patients.
The results of this study establish that patients with 
serum activin B levels significantly elevated above the 
established reference range associate with the symptoms 
of CFS/ME, in contrast to serum activin A. Our data, 
therefore, indicate that the pattern of elevated serum 
activin B together with normal activin A identified a 
group of patients with CFS/ME, as defined by the 2003 
Canadian Criteria. Consequently, this pattern of serum 
activin A and B represents a diagnostic marker, in con-
trast to the failure of other cytokines to define patients 
with CFS/ME. This observation was further confirmed by 
the finding that serum activin A and B levels in the study 
control group, recruited at the same time as the CFS/
ME participants, were not statistically different from the 
established reference ranges [8]. The altered patterns of 
activins contrast with the numerous studies of a wide 
range of serum markers that have been measured previ-
ously seeking a diagnostic test for CFS/ME [2–6]. Serum 
and blood markers available via pathology laboratories 
generally fall within the assay reference interval for CFS/






























































Fig. 1 Mean serum concentrations of a activin A, b activin B and c follistatin levels in study participants diagnosed with chronic fatigue syndrome 
(CFS/ME), compared to a study control group comprising healthy participants (study controls). d Ratio of activin B to follistatin levels (ActB:FST). 
Data are presented as mean ± SEM
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ME patients, as observed for the participants of this 
study.
The repeat of this study with larger patient and control 
cohorts will be a priority for the future, as will the inves-
tigation of activin/follistatin in relation to other forms of 
fatigue. Bias was minimised through the coding regime 
used to protect research participant confidentiality. No 
clinical notes or personal details were attached to the 
activin samples at any time, and the researchers had no 
contact with patients directly or with their medical his-
tories during the planning of the study, and interrogation 
of the data.
Prior studies on the value of cytokines as biomarkers 
is divided, with some studies promoting the efficacy of 
cytokine profiles when considering onset characteristics 
and longitudinal studies [17, 18]. In contrast, reviews of 
a Activin B
(AUC 0.72 ± 0.08: p = 0.01)
b Activin A
(AUC 0.47 ± 0.08: p = 0.70)
c Follistatin
(AUC 0.57 ± 0.10: p = 0.44)
d Interleukin 10
(AUC 0.57 ± 0.09: p = 0.43)
Fig. 2 Receiver Operating Curves (ROC) for a activin B, b activin A, c follistatin and d interleukin 10 (IL-10), for separating CFS/ME participants from 
healthy study controls recruited at the same time. The blue line represents the cytokine and the green line the 50% threshold of Sensitivity versus 1–
Specificity for the protein detected in the CFS/ME or control serum
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the literature concluded that CFS/ME does not involve 
immune dysfunction [19], a conclusion supported by 
experimental studies that included results from CFS/ME 
patients in the context of exercise and sleep deprivation 
[20]. It was noted that interleukin 10 (IL-10) provided 
diagnostic value, but required spinal fluid samples from 
CFS/ME patients [21].
Transforming growth factor-beta (TGF-β) likewise has 
been mentioned as a significant marker [22, 23]. TGF-β 
modulation is also of note because of its role in NK-cell 
regulation and suppression [24], with NK-cell dysfunc-
tion a consistent CFS/ME observation for 25 years [25]. 
TGF-β1 inhibited NK cell DNA synthesis and production 
of cytokines, as well as weakly inhibited cytotoxic activity 
[26], with the inhibition of NK cell activity by TGF-β later 
found to involve the inhibition of mTOR kinase signal-
ling, including post IL-15 stimulation [27].
However, TGF-β1 has a history of challenges in terms 
of biomarker development, involving the need for spe-
cial blood collection methods and the removal of plate-
lets prior to assay, as well as early reports of up to tenfold 
variation in disease studies, in comparison to control 
subjects [28–30]. TGF-β1 variation due to exogenous 
and endogenous factors, therefore, limited its diagnostic 
reliability. This is not true for activin B. Activin B levels 






















































































Fig. 3 Mean serum concentrations of a activin A, b activin B and c follistatin levels in study participants diagnosed with chronic fatigue syndrome 
(CFS/ME) compared to activin/follistatin data from a reference population. Ratio of d activin B to follistatin levels (ActB:FST), e activin A to follistatin 
levels (ActA:FST) and f Ratio of activin B to activin A (ActB:ActA). Data are presented as mean ± SEM
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smoking, allergies or type of medication [8] and to date, 
activin B levels have not been reported to be elevated or 
reduced in other diseases. Together with an established 
reference interval [8, 14], activin B has the potential to be 
a biomarker of clinical utility for CFS/ME, once validated 
on additional cohorts and other clinical criteria [2].
Activin A is a known modulator of the inflammatory 
cascade with its role as a pro-inflammatory cytokine dis-
covered following its rapid elevation after lipopolysac-
charide (LPS) was administered to mice [31], and there 
is evidence that activin B exerts actions similar to activin 
A, for example in muscle wasting and renal injury [32, 
33]. However, others have shown that activin B exerts 
distinct functions to activin A, such as regulating hepci-
din expression during the pathogenesis of inflammation-
induced anaemia via Smad 1/5/8 signalling, while activin 
A exerts its actions through Smad 2/3 signalling [10]. 
Our data shows that levels of activin A and inflammatory 
cytokines were not elevated in CFS/ME patients, indi-
cating an absence of underlying inflammation in these 
patients. The observed elevation of activin B levels, as 
well as elevated activin to follistatin ratios, indicates an 
increased systemic bioavailability of activins; however, 
the mechanisms by which activin B is causally linked 
requires further investigation.
The finding of an elevated serum activin B level also 
raises the possibility that treatment with follistatin may 
be of value in the management of patients with CFS/ME, 
since follistatin, in addition to blocking the actions of 
activin A, also can block the actions of activin B. Further, 
treatment with follistatin has the potential advantage that 
in addition to attenuating the actions of the activins, it 
can also block the actions of myostatin, thus enhancing 
muscle mass [34].
Conclusions
Given the inability to clearly diagnose CFS/ME by the 
measurement of other cytokines, the demonstration that 
the measurement of activins A/B and follistatin enabled 
the identification of a population of CFS/ME patients, 
diagnosed via the Canadian criteria, is significant. These 
results propose that measurements of the activins and fol-
listatin will be of value in separating patients with CFS/ME 
from other disorders that also cause fatigue. These data 
strongly suggest the need for a larger prospective study of 
CFS/ME patients to determine whether the detection of 
elevated serum activin B and normal activin A levels can 
predict the subsequent course for such patients.
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